Skip to main content

Table 2 CPV Case Details

From: Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial

CPV Case Presenting History Stage Gleason Cores PSA NCCN Risk Category PBA score PBA Risk Category Preferred Option
1 Active 60 year old M with increasing urinary frequency T1c 3 + 3 2_12 (<50%) <10 Very Low 15 Low AS
2 Sedentary 78 year old M with hematuria T1c 3 + 3 4_12 (<50%) 7.1 Very Low 15 Low AS
3 Moderately active 73 year old M with urinary frequency and hesitancy T2a 3 + 4 3_12 (20% tumor in 4 s) 14 Intermediate 17 Low AS
4 Quite active 57 year old M with erectile dysfunction and recent prostatitis T2a 3 + 4 7_12 21 High 17 Low AS
5 Moderately active 55 year old M with rising serum PSA levels T1c 3 + 3 4_12 9.8 Very Low 35 Intermediate AS
6 63 year old M, no longer active due to knee osteoarthritis, with suspicious digital rectal examination T1c 3 + 3 6_12 8.9 Low 60 Intermediate AT
7 Active 62 year old M with gross hematuria T1c 3 + 4 3_12 (10% showing) 10.4 Intermediate 20 Low AS
8 Lightly active 75 year old M seen for follow-up of suspicious nodularity on prostate T2a 3 + 4 6_12 8.7 Intermediate 77 High AT
9 Moderately active77 year old M seen in referral for nodule on prostate and high serum PSA T2a 3 + 4 6_12 22.1 High 77 High AT
  1. PBA protein-based assay